Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
India
/
Pharmaceuticals & Biotech
/
Indoco Remedies
INDOCO
Indoco Remedies
US And EU Regulation Will Hamper Long-Term Profitability
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 4 Analysts
Published
10 Jul 25
Updated
09 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
₹207.00
37.7% overvalued
intrinsic discount
09 Aug
₹285.10
Loading
1Y
-12.8%
7D
-2.3%
Author's Valuation
₹207.0
37.7% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
₹207.0
37.7% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-1b
24b
2015
2017
2019
2021
2023
2025
2027
2028
Revenue ₹24.4b
Earnings ₹1.8b
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
14.26%
Pharma revenue growth rate
1.09%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
12.73%
Calculation
₹1.84b
Earnings '28
x
11.94x
PE Ratio '28
=
₹21.94b
Market Cap '28
₹21.94b
Market Cap '28
/
73.07m
No. shares '28
=
₹300.32
Share Price '28
₹300.32
Share Price '28
Discounted to 2025 @ 12.73% p.a.
=
₹209.65
Fair Value '25
